Denifanstat seen to safely treat NASH in Phase 2b clinical trial
Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…
Fatty liver disease
ProSciento, OWL metabolomics team up on NAFLD/NASH trial recruitment
ProSciento and OWL Metabolomics are partnering to find eligible participants for clinical trials for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
VK2809 shows potential in treating NASH-related fibrosis in early study
Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.
Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
Early Study to Test Bioelectronic Treatment for NASH Inflammation
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Exposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- Maralixibat reduces itch in children with biliary atresia: Case series
- Phase 3 trials of treatment combo for hepatitis D expected in 2025
- Doing our part to hasten a cure for our daughter’s PFIC3
- PBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
- Bylvay eases itch over long term in PFIC, Alagille syndrome patients